Boston Scientific’s $1.07bn asset transaction deal with Lumenis was the medical devices industry’s biggest cross border deal of Q1 2021 as cross border deals worth $6.67bn were announced globally in the quarter, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 5.5% over the previous quarter and a drop of 16.4% when compared with the last four-quarter average of $7.98bn.
In terms of number of cross border deals, the sector saw a rise of 17.14% with 135 deals in Q1 2021 against the average of 115.25 deals in the last four-quarters.
In value terms, North America led the activity with cross border deals worth $2.73bn.
medical devices industry cross border deals in Q1 2021: Top deals
The top five medical devices industry cross border deals accounted for 53.8% of the overall value during Q1 2021.
The combined value of the top five cross border deals stood at $3.59bn, against the overall value of $6.67bn recorded for the quarter.
The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction deal with Lumenis
2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific
3) Koninklijke Philips’ $635m acquisition of Capsule Technologies
4) The $591m acquisition of Oxford Immunotec by PerkinElmer
5) Savaria’s acquisition of Handicare Group for $409.7m.
